文献速递炎症性肠病

炎症性肠病患者使用糖皮质激素与严重感染风险:倾向评分匹配研究

Serious Infections in Patients With Inflammatory Bowel Disease and Corticosteroids: A Propensity Score-Matched Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-08-28

基于瑞典全国登记数据(2007-2024),比较不同治疗方案的炎症性肠病患者在合用或不合同糖皮质激素时的严重感染发生率,并按倾向评分1:1匹配直接比较。结果显示,合用糖皮质激素者的严重感染风险显著高于未合用者,且儿童相对风险最高、风险随累积剂量增加。

要点

  • 合用糖皮质激素的IBD患者严重感染风险显著高于未合用者。
  • 儿童中糖皮质激素相关严重感染的相对风险最高。
  • 严重感染相对风险随累积糖皮质激素剂量增加而升高。

核心结论

  • 接受糖皮质激素治疗的IBD患者在各治疗方案中严重感染率均显著高于未接受糖皮质激素者。
  • 率差随年龄组和治疗联合方案不同而变化,儿童相对风险最高且随累积剂量增加。

研究设计与样本

  • 基于瑞典全国登记数据(2007-2024)的倾向评分匹配研究。
  • 共识别145,125个未使用免疫调节剂和进阶治疗的暴露期、82,675个免疫调节剂暴露期、90,181个进阶治疗暴露期。
  • 按糖皮质激素使用分层,并与匹配的普通人群对照(每例≤10)比较,另进行1:1倾向评分匹配直接比较。

主要发现

  • 与普通人群比较,合用糖皮质激素暴露期的严重感染率差范围为3.6-10.2/100人年,aHR范围4.52-15.86。
  • 倾向评分匹配的治疗组内比较中,合用糖皮质激素的严重感染率差范围为3.9-8.5/100人年,aHR范围1.82-3.60。
  • 儿童中糖皮质激素相关严重感染的相对风险最高,且风险随累积糖皮质激素剂量增加而升高。

临床怎么用

  • 在IBD治疗决策中应评估糖皮质激素使用带来的严重感染风险,尤其关注儿童和累积剂量较高者。
  • 研究数据可用于个体化感染风险评估和感染预防策略的考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Absolute risk estimates of serious infections in inflammatory bowel disease (IBD) across therapies and concomitant corticosteroid treatment are limited. We aimed to assess serious infection risk in patients with IBD receiving different therapies, with or without corticosteroids. METHODS: Using nationwide Swedish registers (2007-2024), we compared rates of serious infections in patients with IBD treated with different therapies vs matched population comparators (≤10 per patient), stratified by corticosteroid use. We also performed 1:1 propensity score-matching for direct comparison of infection risk in IBD with or without concomitant corticosteroids exposure across advanced therapies. Incidence rates (IRs) and adjusted hazard ratios (aHRs) with 95% confidence intervals were calculated. RESULTS: We identified 145,125 exposure periods in patients with IBD naïve to immunomodulators and advanced therapies, 82,675 to immunomodulators, and 90,181 to advanced therapies (tumor necrosis factor-α inhibitors with and without immunomodulator, anti-integrins, anti-interleukins, and Janus kinase inhibitors). Across therapies, exposure periods with corticosteroids carried a higher risk of serious infections than periods without, both compared with the general population (IR difference range, 3.6-10.2/100 person-years; aHR range, 4.52-15.86) and in propensity score-matched within therapy group comparisons (IR difference range, 3.9-8.5/100 person-years; aHR, 1.82-3.60). The relative risk was highest in children and increased with cumulative corticosteroid dose. CONCLUSIONS: Patients with IBD receiving corticosteroids had significantly higher rates of serious infections compared with those not receiving corticosteroids across therapies, with rate differences across age groups and combinations of treatments. These data will inform infection risk assessment and consideration of individualized infection-prevention strategies.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Forss A, Axelrad J, Söderling J, et al. Serious Infections in Patients With Inflammatory Bowel Disease and Corticosteroids: A Propensity Score-Matched Study. Clin Gastroenterol Hepatol. 2026. PMID: 42665112. doi:10.1016/j.cgh.2026.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。